Navigation Links
Hepatitis C cured in co-infected HIV patients
Date:7/19/2014

A multicenter team of researchers report that in a phase III clinical trial, a combination drug therapy cures chronic hepatitis C in the majority of patients co-infected with both HIV and hepatitis C.

"In many settings, hepatitis C is now a leading cause of death among HIV co-infected patients," says Mark Sulkowski, M.D., medical director of the Johns Hopkins Infectious Disease Center for Viral Hepatitis and professor of medicine at the Johns Hopkins University School of Medicine. Approximately one-third of HIV patients in the United States have hepatitis C, with an estimated 7 million co-infected patients worldwide.

Because of poor tolerability to the previous standard of treatments for hepatitis C, including injections of interferon-alpha and medications that can have interactions with anti-retroviral medications used to treat HIV, this population of co-infection patients has been considered difficult to treat. Data from this phase III clinical trial were incorporated into the FDA's approval of the new drug, sofosbuvir, last December, so treatment with this all-oral regimen sofosbuvir and ribavirin is considered on-label.

The trial, paid for by the developers of sofosbuvir, Gilead Sciences, is published in the July 23 issue of The Journal of the American Medical Association.

Researchers and doctors enrolled study participants from the United States and Puerto Rico through 34 academic, private practice and community health centers. In total, doctors administered sofosbuvir and ribavirin to a total of 223 HIV-1 patients chronically co-infected with hepatitis C (genotypes 1, 2 or 3) either for 12 weeks (for treatment-naive patients with genotype 2 or 3) or for 24 weeks (for treatment-naive patents with genotype 1 or treatment-experienced patents with genotype 2 or 3). Twelve weeks after treatment ended, researchers tested patients again for hepatitis C infection to determine if treatment was effective.

For treatment-naive patients, 76 percent with genotype 1, 88 percent with genotype 2 and 67 percent with genotype 3 were cured. "We've always termed this to be 'sustained virologic response,'" says Sulkowski, "but we now know that means hepatitis C has been cured." Treatment-experienced patients had even better cure rates: 92 percent for patients with genotype 2 and 94 percent for patients with genotype 3. Seven patients discontinued treatment because of adverse events, but there were no observed adverse effects on HIV or its treatment.

"The likelihood that a patient with chronic, long-standing hepatitis C infection would have spontaneous cure is near zero," says Sulkowski, "so if these patients had not been treated, none would have been cured." Because of this, typically the control group of patients in a clinical trial undergoes the standard-of-care treatment, which for hepatitis C is weekly Interferon injections and twice-daily ribavirin orally. However, neither the investigators nor the potential clinical trial participants were willing to accept a therapy that for HIV co-infected patients had both low efficacy and poor tolerability.

In addition, says Sulkowski, "Doctors and patients alike recognize the idea that it would be difficult, if not impossible, to randomize clinical trial participants to an injectable treatment (interferon) that's linked to many side effects versus an oral treatment (sofosbuvir plus ribavirin)." For these reasons, the clinical trial, named PHOTON-1, was open-label, nonrandomized and uncontrolled. "The PHOTON-1 study represents the first clinical trial to demonstrate that we can cure hepatitis C in patients with HIV co-infection without the use of interferon," says Sulkowski. "As such, it represents a transformative step in our approach to this therapeutic area."


'/>"/>
Contact: Lauren Nelson
lnelso35@jhmi.edu
410-955-8725
Johns Hopkins Medicine
Source:Eurekalert

Related medicine news :

1. EurekaMag.com Publishes 64,900 New Studies on Hepatitis C
2. Antiviral therapy can prevent liver cancer in chronic hepatitis B patients
3. Antiviral therapy may prevent liver cancer in hepatitis B patients
4. Hepatitis C reactivation doesnt worsen survival for HIV+ patients diagnosed with lymphoma
5. Paper-based diagnostics, made with a scrapbooking tool, could curb hepatitis C pandemic
6. Researchers propose treating prison population to fight US hepatitis C epidemic
7. Gene variants protect against relapse after treatment for hepatitis C
8. Prevalence of hepatitis C infection found to vary widely among Hispanics
9. Protein links liver cancer with obesity, alcoholism, and hepatitis
10. Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022
11. Advanced Male Medical Center Offers Hepatitis C Testing in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... April 29, 2017 , ... More than half of Americans suffering from ... in their leisure time that causes hearing loss? May 1 marks the beginning of ... to hearing loss, as well as schedule a hearing evaluation for anyone with concerns ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for Health Care ... of America (HCAOA). This agreement allows HCAOA members to receive special pricing on ... on Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of New Jersey ... “A” and its outlook as “stable.” At the same time, the ratings agency cautioned ... recent years, dip below “capital adequacy” thresholds required for its strong rating. , “Horizon ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps ... fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ...
(Date:4/28/2017)... Texas (PRWEB) , ... April 28, 2017 , ... The ... plaque in recently to the labor and delivery team at Women’s Hospital at Renaissance ... mothers who give birth at the hospital and decide to donate. , “Women’s ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... April 18, 2017 Viverae ® , a ... the integration of IBM ® Watson Campaign Automation, ... targeted communications for a personalized experience. Through digital engagement, ... their health in real time. The enhanced experience drives ... to members, wherever they are in their journey to ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., ... case series to be presented at the 2017 National ... begins today and continues through April 22. Physicians will ... , used to assess risk for acute kidney injury ... heart failure (ADHF). Elevated levels of ...
(Date:4/18/2017)... 2017  Socionext Inc. and SOINN Inc. today ... in which Socionext extracts and delivers biometrics data ... initial results in reading ultrasound images from Socionext,s ... The results will be introduced at Medtec Japan, ... booths 4505 & 4507. In this ...
Breaking Medicine Technology: